Eltrombopag for management of <font color="blue">chronic_2</font> <font color="blue">immune_2</font> <font color="blue">thrombocytopenia_2</font> ( RAISE ) : a 6-month , randomised , phase 3 study . 
<br>
<br> BACKGROUND Eltrombopag is an oral thrombopoietin receptor agonist for the treatment of thrombocytopenia . We aimed to compare the response to once daily eltrombopag versus placebo <font color="blue">in_1</font> <font color="blue">patients_5</font> <font color="blue">with_5</font> <font color="blue">chronic_5</font> <font color="blue">immune_5</font> <font color="blue">thrombocytopenia_5</font> <font color="blue">during_1</font> <font color="blue">a_1</font> <font color="blue">6-month_1</font> <font color="blue">period_1</font> <font color="blue">._1</font> 
<br> METHODS <font color="blue">We_1</font> <font color="blue">undertook_1</font> <font color="blue">a_1</font> <font color="blue">phase_1</font> <font color="blue">3_1</font> <font color="blue">,_1</font> <font color="blue">double_1</font> <font color="blue">-_1</font> <font color="blue">blind_1</font> <font color="blue">,_1</font> <font color="blue">placebo_1</font> <font color="blue">-_1</font> <font color="blue">controlled_1</font> <font color="blue">study_1</font> <font color="blue">in_1</font> <font color="blue">adults_4</font> <font color="blue">with_4</font> <font color="blue">previously_4</font> <font color="blue">treated_4</font> <font color="blue">immune_4</font> <font color="blue">thrombocytopenia_4</font> <font color="blue">of_4</font> <font color="blue">more_4</font> <font color="blue">than_4</font> <font color="blue">6_4</font> <font color="blue">months_4</font> <font color="blue">'_4</font> <font color="blue">duration_4</font> <font color="blue">who_4</font> <font color="blue">had_4</font> <font color="blue">baseline_4</font> <font color="blue">platelet_4</font> <font color="blue">counts_4</font> <font color="blue">lower_4</font> <font color="blue">than_4</font> <font color="blue">30,000_4</font> <font color="blue">per_4</font> <font color="blue">μL._4</font> <font color="blue">Patients_2</font> <font color="blue">were_2</font> <font color="blue">randomly_2</font> <font color="blue">allocated_2</font> <font color="blue">(_1</font> <font color="blue">in_1</font> <font color="blue">a_1</font> <font color="blue">2:1_1</font> <font color="blue">ratio_1</font> <font color="blue">)_1</font> <font color="blue">treatment_1</font> <font color="blue">with_1</font> <font color="blue">local_1</font> <font color="blue">standard_1</font> <font color="blue">of_1</font> <font color="blue">care_1</font> <font color="blue">plus_1</font> <font color="blue">50_1</font> <font color="blue">mg_1</font> <font color="blue">eltrombopag_1</font> <font color="blue">or_1</font> <font color="blue">matching_1</font> <font color="blue">placebo_1</font> <font color="blue">once_1</font> <font color="blue">daily_1</font> <font color="blue">for_1</font> <font color="blue">6_1</font> <font color="blue">months_1</font> <font color="blue">._1</font> Randomisation was done centrally with a computer - generated randomisation schedule and was <font color="blue">stratified_1</font> <font color="blue">by_1</font> <font color="blue">baseline_1</font> <font color="blue">platelet_1</font> <font color="blue">count_1</font> <font color="blue">(_1</font> <font color="blue">≤_1</font> <font color="blue">15,000_1</font> <font color="blue">per_1</font> <font color="blue">μL_1</font> <font color="blue">)_1</font> <font color="blue">,_1</font> <font color="blue">use_1</font> <font color="blue">of_1</font> <font color="blue">treatment_1</font> <font color="blue">for_1</font> <font color="blue">immune_1</font> <font color="blue">thrombocytopenia_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">splenectomy_1</font> <font color="blue">status_1</font> <font color="blue">._1</font> <font color="blue">Patients_2</font> <font color="blue">,_2</font> <font color="blue">investigators_2</font> <font color="blue">,_2</font> <font color="blue">and_2</font> <font color="blue">those_2</font> <font color="blue">assessing_2</font> <font color="blue">data_2</font> <font color="blue">were_2</font> <font color="blue">masked_2</font> <font color="blue">to_2</font> <font color="blue">allocation_2</font> <font color="blue">._2</font> Dose modifications were made on the basis of platelet response . <font color="blue">Patients_1</font> <font color="blue">were_1</font> <font color="blue">assessed_1</font> <font color="blue">for_1</font> <font color="blue">response_1</font> <font color="blue">to_1</font> <font color="blue">treatment_1</font> ( defined as a platelet count of 50,000 - 400,000 per μL ) weekly during the first 6 weeks and at least once every 4 weeks thereafter ; the primary endpoint was the odds of response to eltrombopag versus placebo . Analysis was by intention to treat . This study is registered at ClinicalTrials.gov , number NCT00370331 . 
<br> FINDINGS <font color="blue">Between_2</font> <font color="blue">Nov_2</font> <font color="blue">22_2</font> <font color="blue">,_2</font> <font color="blue">2006_2</font> <font color="blue">,_2</font> <font color="blue">and_2</font> <font color="blue">July_2</font> <font color="blue">31_2</font> <font color="blue">,_2</font> <font color="blue">2007_2</font> <font color="blue">,_2</font> <font color="blue">197_5</font> <font color="blue">patients_5</font> <font color="blue">were_1</font> <font color="blue">randomly_1</font> <font color="blue">allocated_1</font> <font color="blue">to_1</font> <font color="blue">treatment_1</font> <font color="blue">groups_1</font> and were included in the intention - to - treat analysis ( 135 eltrombopag , 62 placebo ) . <font color="blue">106_1</font> <font color="blue">(_1</font> <font color="blue">79%_1</font> <font color="blue">)_1</font> <font color="blue">patients_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">eltrombopag_1</font> <font color="blue">group_1</font> <font color="blue">responded_1</font> <font color="blue">to_1</font> <font color="blue">treatment_1</font> <font color="blue">at_1</font> <font color="blue">least_1</font> <font color="blue">once_1</font> <font color="blue">during_1</font> <font color="blue">the_1</font> <font color="blue">study_1</font> <font color="blue">,_1</font> <font color="blue">compared_1</font> <font color="blue">with_1</font> <font color="blue">17_1</font> <font color="blue">(_1</font> <font color="blue">28%_1</font> <font color="blue">)_1</font> <font color="blue">patients_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">placebo_1</font> <font color="blue">group_1</font> <font color="blue">._1</font> <font color="blue">The_1</font> <font color="blue">odds_1</font> <font color="blue">of_1</font> <font color="blue">responding_1</font> <font color="blue">were_1</font> <font color="blue">greater_1</font> <font color="blue">in_1</font> <font color="blue">patients_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">eltrombopag_1</font> <font color="blue">group_1</font> compared with those in the placebo group throughout the 6-month treatment period ( odds ratio 8·2 , 99% CI 3·59 - 18·73 ; p<0·0001 ) . <font color="blue">37_1</font> <font color="blue">(_1</font> <font color="blue">59%_1</font> <font color="blue">)_1</font> <font color="blue">patients_1</font> <font color="blue">receiving_1</font> <font color="blue">eltrombopag_1</font> <font color="blue">reduced_1</font> <font color="blue">concomitant_1</font> <font color="blue">treatment_1</font> versus ten ( 32% ) patients receiving placebo ( p=0·016 ) . <font color="blue">24_1</font> <font color="blue">(_1</font> <font color="blue">18%_1</font> <font color="blue">)_1</font> <font color="blue">patients_1</font> <font color="blue">receiving_1</font> <font color="blue">eltrombopag_1</font> <font color="blue">needed_1</font> <font color="blue">rescue_1</font> <font color="blue">treatment_1</font> compared with 25 ( 40% ) patients receiving placebo ( p=0·001 ) . <font color="blue">Three_1</font> <font color="blue">(_1</font> <font color="blue">2%_1</font> <font color="blue">)_1</font> <font color="blue">patients_1</font> <font color="blue">receiving_1</font> <font color="blue">eltrombopag_1</font> <font color="blue">had_1</font> <font color="blue">thromboembolic_1</font> <font color="blue">events_1</font> compared with none in patients on placebo . Nine ( 7% ) eltrombopag - treated patients and two ( 3% ) in the placebo group had mild increases in alanine aminotransferase concentration , and five ( 4% ) eltrombopag - treated patients ( vs none allocated to placebo ) had increases in total bilirubin . <font color="blue">Four_1</font> <font color="blue">(_1</font> <font color="blue">7%_1</font> <font color="blue">)_1</font> <font color="blue">patients_1</font> <font color="blue">taking_1</font> <font color="blue">placebo_1</font> <font color="blue">had_1</font> <font color="blue">serious_1</font> <font color="blue">bleeding_1</font> <font color="blue">events_1</font> <font color="blue">,_1</font> compared with one ( < 1% ) patient treated with eltrombopag . 
<br> INTERPRETATION Eltrombopag is effective for management of chronic immune thrombocytopenia , and <font color="blue">could_1</font> <font color="blue">be_1</font> <font color="blue">particularly_1</font> <font color="blue">beneficial_1</font> <font color="blue">for_1</font> <font color="blue">patients_3</font> <font color="blue">who_2</font> <font color="blue">have_2</font> <font color="blue">not_2</font> <font color="blue">responded_2</font> <font color="blue">to_2</font> <font color="blue">splenectomy_2</font> <font color="blue">or_2</font> <font color="blue">previous_2</font> <font color="blue">treatment_2</font> <font color="blue">._2</font> These benefits should be balanced with the potential risks associated with eltrombopag treatment . 
<br> FUNDING GlaxoSmithKline .